A Cosmetics Complaint Arrived on Friday. Who Owns the 15-Business-Day MoCRA Report?
Trace a cosmetics complaint from receipt through serious-adverse-event review, label recovery, FDA submission and one-year follow-up under MoCRA.
Signals to watch
- A US cosmetics complaint mentions hospitalisation, infection, significant disfigurement or medical intervention while the responsible person remains unstated
- The brand has a receipt date and product name but cannot recover the retail-packaging label copy required with the report
- An initial FDA submission exists, yet new medical information received within one year has no follow-up owner or 15-business-day calculation
A cosmetics complaint starts the MoCRA reporting handoff when the responsible person receives it, not when a service provider later opens a ticket. If the event meets the serious-adverse-event definition, the responsible person has 15 business days to report it to the Food and Drug Administration (FDA) and must include the retail-packaging label. The first commercial question is therefore not “Can you file this?” It is “Who is the responsible person, when did they receive the information, and what evidence supports seriousness?”
This is the distinction a cosmetics regulatory operations or adverse-event service provider’s business-development lead needs in authorised beauty-brand, contract-manufacturer and regulatory Telegram groups. A complaint becomes worth human review when the messages point to a US product, a possible serious outcome, a known receipt event and an unresolved owner or evidence gap. Waiting until next week can consume several of the 15 business days while the label version and medical contact remain scattered.
Friday, 16:20 — intake has a clock but not yet a conclusion
Consider this illustrative composite fragment; it is not a customer message:
“US customer says the peel caused an infection and urgent care prescribed antibiotics. Came through distributor support. We need the box label from the old batch.”
The message contains a US use, an infection, medical treatment, a distributor support channel and a missing label. It does not identify the product, reporter, patient, receipt timestamp, named company on the label, batch, diagnosis, hospitalisation, seriousness reviewer or consent to obtain records.
Under FDA’s current cosmetics complaint page, the responsible person is the manufacturer, packer or distributor whose name appears on the product label under the applicable labelling law. The contract manufacturer that made the batch is not automatically the responsible person. The support vendor that first read the ticket is not automatically the responsible person either.
The first handoff stop is an intake receipt containing the original wording, product identity, contact route, date and time received by the responsible person, and the person who accepted it. Preserve what is unknown. “Friday” without a timezone or ticket timestamp is not enough to calculate a deadline.
Monday — seriousness review needs the outcome, not a keyword
MoCRA added section 605 to the Federal Food, Drug, and Cosmetic Act. FDA describes a serious adverse event as one resulting in death, a life-threatening experience, inpatient hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect, infection, or significant disfigurement—including specified serious and persistent skin, burn, hair-loss or appearance outcomes—or requiring medical or surgical intervention, based on reasonable medical judgment, to prevent one of those outcomes.
The word “infection” in the fragment is relevant because infection is listed. It does not let a salesperson decide the case. The authorised reviewer still needs what happened, timing in relation to use, medical information, product details and any evidence that changes the interpretation.
Write one decision record with three outcomes:
- serious on the evidence currently available, with the supporting criterion and reviewer;
- not currently serious, with the evidence and voluntary-reporting decision preserved; or
- information insufficient, with a named request for the missing record.
The third outcome is not a reason to lose the intake date. It means the responsible person must manage the deadline while collecting enough information to submit an accurate initial report.
The label copy is part of the report, not decoration
FDA states that the responsible person must include a copy of the label on or within the cosmetic product’s retail packaging. That requirement exposes a common operational failure: the complaint references a product name, but the team retrieves the current website image rather than the label for the reported package or batch.
The handoff should identify the product name, size or variant, lot or batch if available, where it was obtained, and which label artifact corresponds to the package. If the exact label cannot yet be recovered, record the search and uncertainty. Do not silently attach the newest artwork.
The MoCRA facility-renewal request concerns a different legal record. Facility registration or product listing data may help identify the company or product, but it does not replace the adverse-event intake and label evidence. A Cosmetics Direct SPL validation error concerns structured product-listing transmission, not a serious-event report.
Choose the FDA route only after the owner and evidence are clear
FDA’s page current on 15 August 2026 lists two electronic industry routes and a paper route. Database-to-database submitters can send individual case safety reports in XML through the Electronic Submissions Gateway. Companies without that infrastructure can use the Safety Reporting Portal, which requires registration and accepts individual manual submissions rather than batch submission. Paper Form FDA 3500A remains described with its instructions and supporting attachment route.
This is a routing choice, not three different deadlines. The handoff should name the submitting organisation, account owner, selected route, draft owner, quality check, actual submission time and FDA receipt. “3500A completed” is not the same as “FDA received it.”
TOP Prospect can group fragments from Telegram sources a user deliberately connects and is authorised to access, retaining original message, source, time, summary and ranking reason for human review. It cannot read the brand’s support desk, decide seriousness, obtain medical records, submit an FDA report or contact the complainant. Pricing and access options describe the discovery product, not adverse-event reporting services.
One year of follow-up needs its own owner
FDA states that if the responsible person receives medical or other information about the adverse event within one year after the initial report, that new information must be sent to FDA within 15 business days. This creates a second receipt event. It should not be hidden inside the original case notes.
A durable record includes:
| Stop | Minimum evidence | Accountable role |
|---|---|---|
| Intake | Original complaint, receipt timestamp, product and contact route | Responsible-person intake owner |
| Review | Seriousness criterion, evidence, reviewer and decision time | Medical or regulatory reviewer |
| Label | Retail-packaging label tied to the reported product | Product or artwork owner |
| Submission | Route, payload or form, sent time and FDA receipt | Regulatory submission owner |
| Follow-up | New-information receipt, link to initial report and new deadline | Case follow-up owner |
This five-stop record is the article’s original contribution. It tells a service provider whether the actual need is intake design, medical review coordination, label recovery, submission operations or follow-up tracking without promising a legal outcome from chat fragments.
Key facts
- MoCRA added section 605 to the FD&C Act for cosmetics adverse-event reporting.
- The responsible person is the manufacturer, packer or distributor whose name appears on the cosmetic label under the applicable labelling provision.
- A serious adverse event associated with use of a cosmetic product in the United States must be reported to FDA within 15 business days.
- The report must include a copy of the label on or within the retail packaging.
- New medical or other information received within one year of the initial report must be submitted within 15 business days.
- FDA currently describes direct electronic transmission, the Safety Reporting Portal and Form FDA 3500A submission routes for industry.
FAQ
Who is the responsible person under MoCRA?
FDA defines the responsible person as the manufacturer, packer or distributor whose name appears on the cosmetic product label under the applicable FD&C Act or Fair Packaging and Labeling Act provision.
When is a cosmetics serious adverse event report due?
The responsible person must report a serious adverse event associated with use of a cosmetic product in the United States to FDA within 15 business days and include a copy of the label on or within the retail packaging.
What happens when new medical information arrives later?
If the responsible person receives medical or other information about the event within one year after the initial report, the new information must be submitted to FDA within 15 business days.
Does every rash or complaint require a mandatory serious-adverse-event report?
No. The event must meet the statutory serious-adverse-event definition. Non-serious events can be reported voluntarily, but the mandatory route should not be assumed from a brief group message.
The request is ready for a scope call when the responsible person, receipt timestamp, seriousness reviewer, reported label and submission owner can be named. Until then, the missing work is evidence recovery—not a promise that a report has been completed.
Frequently asked questions
Who is the responsible person under MoCRA?
FDA defines the responsible person as the manufacturer, packer or distributor whose name appears on the cosmetic product label under the applicable FD&C Act or Fair Packaging and Labeling Act provision.
When is a cosmetics serious adverse event report due?
The responsible person must report a serious adverse event associated with use of a cosmetic product in the United States to FDA within 15 business days and include a copy of the label on or within the retail packaging.
What happens when new medical information arrives later?
If the responsible person receives medical or other information about the event within one year after the initial report, the new information must be submitted to FDA within 15 business days.
Does every rash or complaint require a mandatory serious-adverse-event report?
No. The event must meet the statutory serious-adverse-event definition. Non-serious events can be reported voluntarily, but the mandatory route should not be assumed from a brief group message.
Sources and further reading
How a Signal worth attention is found
See how Top Prospect finds and organizes Signals worth checking, keeps the original Telegram context, removes duplicates, and helps you decide what to review first. You decide whether to follow up and what to do next.
